+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07877272

Reclassifying Treatment for High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease Using Endohepatology A Prospective Multicenter Observational Study

Led by University Hospital Muenster · Updated on 2026-10-20

500

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how endohepatology may change treatment decisions for adults at high risk of metabolic dysfunction-associated steatotic liver disease MASLD. This prospective observational study focuses on comparing treatment indications based on non-invasive tests versus advanced endohepatology assessments including liver biopsy and portal pressure measurements. The study aims to understand if these endohepatology methods provide important additional information for managing MASLD and related liver conditions. Participants first undergo clinical assessments, blood tests, abdominal ultrasound, and various non-invasive liver stiffness and fibrosis tests. Those with abnormal or unclear results receive a single-session endohepatology evaluation involving upper gastrointestinal endoscopy with EUS-guided shear-wave elastography, portal pressure measurement, and liver biopsy. Treatment indications based on these detailed assessments are compared with the initial non-invasive results. Follow-up continues for 24 months following enrollment. During the study, participants have several assessments including laboratory tests, imaging, and biopsies as applicable and consented. Samples like blood, saliva, stool, and tissue biopsies may be collected for translational research. Researchers measure changes in treatment indications after endohepatology, the presence of liver fibrosis and portal hypertension, and monitor for adverse events and liver-related outcomes over two years. Safety is closely followed, especially after invasive procedures, to ensure participant well-being throughout the study.

CONDITIONS

Brief Title

Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD

Research Team

M

Michael Prof. Dr. Praktiknjo, MD PhD

D

Dominik Dr. van de Loo, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here